Malezya - İngilizce - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

medispec (m) sdn.bhd - formoterol fumarate dihydrate -

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

fannin (uk) ltd - salmeterol - pressurised inhalation, suspension - 25 microgram(s) - selective beta-2-adrenoreceptor agonists; salmeterol

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

fannin limited - salmeterol - pressurised inhalation, suspension - 25 microgram(s) - selective beta-2-adrenoreceptor agonists; salmeterol

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

laboratorios liconsa, s.a. - formoterol fumarate - inhalation powder, hard capsule - 12 microgram(s) - selective beta-2-adrenoreceptor agonists; formoterol

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - salmeterol xinafoate, quantity: 36.32 microgram/actuation (equivalent: salmeterol, qty 25 microgram/actuation); fluticasone propionate, quantity: 250 microgram/actuation - inhalation, pressurised - excipient ingredients: norflurane - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include: - patients on effective maintenance doses of long-acting beta-2 agonists and inhaled corticosteroids. - patients who are symptomatic on current inhaled corticosteroid therapy.,for the symptomatic treatment of patients with severe copd (fev1 less than 50 precent predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. fluticasone propionate/salmeterol (125 microgram/25 microgram and 250 microgram/25 microgram) is not indicated for the initiation of bronchodilator therapy in copd.